Literature DB >> 8978282

Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization.

R Sungaran1, B Markovic, B H Chong.   

Abstract

Thrombopoietin (TPO) is the primary hematopoietic growth factor involved in the regulation of platelet production. Although the kidney, liver, bone marrow (BM), and spleen have been identified as the major sources of TPO production, the precise cellular location of TPO mRNA expression in these tissues remains unknown. We have identified the cells expressing TPO mRNA in the human kidney, liver, and BM using an in situ hybridization assay. In the BM of individuals with normal platelet counts, the hybridization signal was too weak to allow identification of the TPO mRNA expressing cells. However, in thrombocytopenic subjects with aplastic anemia, postchemotherapy marrow aplasia, and immune thrombocytopenia, the stromal cells showed strong TPO mRNA expression. In the human subjects with normal platelet counts, the cells of the proximal convoluted tubules of the kidney showed consistent positive staining whereas the signal in the cells of the distal convoluted tubules was less consistent. Strong hybridization signal was also evident in the hepatocytes. The hybridization signal in the spleen, even in thrombocytopenic subjects, was too weak to allow confident identification of the cells expressing TPO mRNA. In all subjects, the interstitial cells and endothelial cells of the liver and spleen, the renal peritubular cells, and the hematopoietic precursor cells of the BM showed no TPO mRNA expression. Our data suggest that TPO mRNA expression in the human BM may be modulated by platelet mass.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978282

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Thrombopoietin in human milk.

Authors:  Kousaku Matsubara; Takashi Kato; Hiroshi Miyazaki
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

Review 3.  Regulating billions of blood platelets: glycans and beyond.

Authors:  Renata Grozovsky; Silvia Giannini; Hervé Falet; Karin M Hoffmeister
Journal:  Blood       Date:  2015-09-01       Impact factor: 22.113

Review 4.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 5.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 6.  Historical review: megakaryopoiesis and thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

7.  The last intron of the human thrombopoietin gene enhances expression in milk of transgenic mice.

Authors:  Yan Li; Mingqian Zhou; Hongwei Zhou; Yunshan Ning
Journal:  Funct Integr Genomics       Date:  2013-11-28       Impact factor: 3.410

Review 8.  It's reticulated: the liver at the heart of atherosclerosis.

Authors:  Prabhakara R Nagareddy; Sunil K Noothi; Michelle C Flynn; Andrew J Murphy
Journal:  J Endocrinol       Date:  2018-05-02       Impact factor: 4.286

9.  The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling.

Authors:  Renata Grozovsky; Antonija Jurak Begonja; Kaifeng Liu; Gary Visner; John H Hartwig; Hervé Falet; Karin M Hoffmeister
Journal:  Nat Med       Date:  2014-12-08       Impact factor: 53.440

Review 10.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.